Cabozantinib and Pembrolizumab in Metastatic Pancreas

Inclusion Criteria: * Diagnosis of pancreatic ductal adenocarcinoma * Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies * Patients must have adequate organ function Exclusion Criteria: * Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation * Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention * Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation * Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy * Clinically significant cardiovascular disease * Uncontrolled hypertension * Inability to swallow tablets